The maintenance and monitoring of perioperative blood volume by Iijima, Takehiko et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
The maintenance and monitoring of perioperative blood volume
Iijima, Takehiko; Brandstrup, Birgitte; Rodhe, Peter; Andrijauskas, Audrius; Svensen, Christer
H
Published in:
Perioperative Medicine
DOI:
10.1186/2047-0525-2-9
Publication date:
2013
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Iijima, T., Brandstrup, B., Rodhe, P., Andrijauskas, A., & Svensen, C. H. (2013). The maintenance and
monitoring of perioperative blood volume. Perioperative Medicine, 2, [9]. https://doi.org/10.1186/2047-0525-2-9
Download date: 03. Feb. 2020
Perioperative
Medicine 
Iijima et al. Perioperative Medicine 2013, 2:9
http://www.perioperativemedicinejournal.com/content/2/1/9REVIEW Open AccessThe maintenance and monitoring of
perioperative blood volume
Takehiko Iijima1, Birgitte Brandstrup2, Peter Rodhe3, Audrius Andrijauskas4 and Christer H Svensen3*Abstract
The assessment and maintenance of perioperative blood volume is important because fluid therapy is a routine
part of intraoperative care. In the past, patients undergoing major surgery were given large amounts of fluids
because health-care providers were concerned about preoperative dehydration and intraoperative losses to a third
space. In the last decade it has become clear that fluid therapy has to be more individualized. Because the exact
determination of blood volume is not clinically possible at every timepoint, there have been different approaches
to assess fluid requirements, such as goal-directed protocols guided by invasive and less invasive devices.
This article focuses on laboratory volume determination, capillary dynamics, aspects of different fluids and how to
clinically assess and monitor perioperative blood volume.
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Fluid therapy is a routine part of intraoperative anesthetic
and surgical practice, and there is increasing evidence that
fluid therapy can affect perioperative outcomes [1-5]. The
goals of perioperative fluid management are to restore and
maintain blood volume, secure adequate perfusion to per-
tinent tissues, and avoid excessive administration of fluids.
Traditionally, fluid therapy consisted of infusing large
volumes of crystalloids, which often resulted in postopera-
tive body weight gain [6]. This treatment was based on the
premise that patients were hypovolemic due to fasting and
bowel preparation. Furthermore, it was believed, based on
questionable tracer methods, that surgery caused extracel-
lular contraction that needed replacement [7-9]. In recent
years, fasting rules and patient preparation have changed
and the idea that one must replace fluid allocated to
the third space has mostly been abandoned [10]. Care pro-
viders are also now more prone to administer vasopres-
sors instead of fluids to offset the hypotension caused by
general or neuraxial anesthesia [11-13]. Several random-
ized clinical trials have tested the efficacy of different fluid
protocols [14-16], and many protocols aim to achieve either* Correspondence: christer.svensen@sodersjukhuset.se
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reproduction in any medium, provided the orzero fluid balance or a near maximum stroke volume using
both invasive and minimally invasive devices [17].
This article focuses on laboratory volume determination,
capillary dynamics, different fluids and how to clinically
assess and monitor perioperative blood volume.Body fluid compartments
The amount of water found in the body, total body water
(TBW), can be assessed indirectly by any method capable
of measuring body fat or fat-free mass such as hydro-
densitometry, dual-energy x-ray absorptiometry or total
body potassium levels. The amount of body fat thus influ-
ences the TBW: the more fat gives relatively less water
[18]. The anatomical view of fluid distribution is usually
represented as distinct compartments with fixed volumes.
TBW comprises approximately 60% of the lean body
mass, or the equivalent of 42 L in a normal-sized adult
man. This volume can be subdivided into an intracellular
fluid space (ICF), which consists of approximately 28 L,
and an extracellular fluid volume (ECV), which occupies
approximately 14 L. The ECV consists of the plasma
volume (PV, 3 L) and the interstitial fluid space (ISF, 11 L).
The blood volume (BV, 5 L) consists of the PV and the red
cell mass or blood cells (2 L). The red blood cell mass is
usually expressed as a percentage of the total blood
volume and is referred to as the hematocrit (Figure 1).
The osmolality in the ECV is 290 mosmol/kg. The ECVtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Body fluid compartments. Amounts in liters. mEq/L is milliequivalents per liter. Reproduced with permission [19]. ECV: extracellular
volume (PV + ISF); ICF: intracellular fluid space; ISF: interstitial fluid space; IVS: intravascular space; PV: plasma volume.
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(Na+) and potassium (K+). The high Na+ (142 mmol/L)
and low K+ (4.3 mmol/L) concentrations in the ECV are
responsible for maintaining the ECV, while the high K+
(139 mmol/L) and low Na+ (12 mmol/L) concentrations
in the ICF are required for maintaining an electric poten-
tial across cell membranes. The capillary endothelial wall,
however, is readily permeable to electrolytes. Oncotically
active molecules together with an intact wall are necessary
to create and maintain a colloid osmotic pressure (COP)
of 25 mm Hg inside the vascular lumen. Because the inter-
stitial COP is approximately 5 mm Hg, the intravascular
volume remains intact. This will be discussed further in
the section on the capillary wall and the glycocalyx.
Estimation of body compartment volumes
TBW can be estimated with isotopically labeled water
using deuterium or tritium. The ECV can be estimated
using isotopes of bromide (82Br-) or sulfate (35SO4
2-) and
the ICF is obtained as the difference between TBW and
the ECV. The PV can be estimated using either isotope-
labeled albumin or different dyes. The red cell mass, or
the hematocrit, can be estimated using 51Cr-labeled red
cells. Together the PV and the hematocrit make up the
total BV. The ISF is the result of subtracting the BV
from the ECV. These are static measurements, with iso-
topes taking different times to equilibrate and can hardly
be used for clinical purposes.
Plasma volume
The PV can be estimated using radio-iodinated serum al-
bumin (RISA) with the 125I isotope [19,20]. The drawback
of this method, besides its high level of radioactivity, is
that albumin leaks through the capillaries into the intersti-
tial fluid and this tends to give an overestimation of the
distribution volume. Variation coefficients are between 3%and 4% [21]. Other commonly used agents for measuring
the PV are Evans Blue, a dye that binds to albumin, and
indocyanine green (ICG), a dye that binds to globulin [22].
The main advantage of these dyes is that they are non-
radioactive and can achieve the same level of precision as
that obtained with 125I, although they are not without
their own drawbacks.Blood volume
BV is defined as the total volume of blood in the body,
and includes blood stored in the spleen, liver and bone
marrow. Of the total circulating BV, 70% to 80% is
contained in the venous circulation and in the visceral
organs in particular. In 1854, Welcker bled animals to
death, washed out the blood vessels and determined the
hemoglobin content of the blood that had been
obtained. He concluded that the blood constituted one-
thirteenth of the total body weight in mammals. Many
textbooks state that BV is approximately 75 mL/kg for
adult men and 65 mL/kg for adult women, or 7% to 8%
of body weight [23], and that the BV is slightly higher
per kilogram in younger subjects [24]. Formulas based
solely on body weight, however, can be misleading.
Nadler included height in the estimate defining formulas
that have been used frequently [23]. Prediction of BV
based on body surface area may be more accurate in that
this method compensates for differences in adiposity, and
the International Council for Standardization in Haema-
tology recommends formulas based on this value [25].
Blood volumes vary considerably, both between individ-
uals and within the same individual [26,27]. Guyton and
Hall showed that BV varies between individuals depending
on gender and weight [28]. Furthermore, BV can vary
within an individual according to oxygen consumption, as
has been shown in sports medicine [29] and Iijima and
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tients are subjected to anesthesia [30].
Hemorrhage consists of both red cells and plasma
water. It is compensated for by an initial resetting of the
precapillary and postcapillary sphincters leading to the
transcapillary refill state that transports fluid and protein
from the interstitial space to the intravascular space [31].
Furthermore, cells become resistant to insulin resulting
in hyperglycemia [32]. This causes an osmotic gradient
and water flows through the cell membranes to maintain
the BV while albumin is transported from the interstitium
to the intravascular space through lymph channels
[32-35]. Jacob et al. found that BV did not change signifi-
cantly after fasting [13]. Previous work that has examined
changes in fluid spaces following thoracic surgery has
shown that there is a postoperative decrease in BV of 6%
to 19% compared to preoperative values [36-39]. Results
from abdominal surgery, in contrast, have been inconsis-
tent. Shires et al. found that postoperative BV decreased
compared to the preoperative volume, but in this study
the lost blood was not replaced [9]. Ariel found that the
preoperative BV was higher than the BV immediately
following surgery, but had returned to preoperative levels
the following morning [40]. In abdominal and orthopedic
surgery, BV does not change significantly from the pre-
operative value [41-48]. All the above-mentioned trials of
patients undergoing thoracic, abdominal or orthopedic
surgery used 51Cr to measure red cell volume and albumin
labeled with 131I or 125I to measure plasma volume. Rehm
and co-workers, using a dye method for measurement,
found that the PV was unchanged despite excessive infu-
sions of crystalloid, and they confirmed that, for patients
undergoing surgery for ovarian cancer, albumin leaves the
circulation in ways other than direct blood loss [48].
Hormones in control of regulation of volume
BV and the volumes of various other compartments are
also controlled by several hormones such as antidiuretic
hormone (ADH), catecholamines, the renin-angiotensin-
aldosterone system (RAAS), natriuretic peptides (ANP),
erythropoietin and locally active neurohormonal factors.
These hormones are secreted in response to the stimula-
tion of sensors located in the kidneys and other sites such
as the atria and ventricles of the heart. The distribution of
water between the intravascular and extravascular spaces is
regulated by modified Starling forces in combination with
alteration of the vascular endothelial glycocalyx lining [15].
The sympatho-adreno-medullary axis and the hypothal-
amic periventricular nucleus are activated by increases in
stressful stimuli [49]. The former facilitates the release of
catecholamines and activates the sympathetic nervous
system and the latter increases the secretion of cortisol and
adrenocorticotropic hormone. These signals trigger the an-
terior pituitary gland to stimulate ADH secretion, which isthe most potent hormone for maintaining fluid homeosta-
sis. Catecholamines have an impact on the heart and on
the regulation of peripheral vessels. Iijima et al. described
a pediatric patient with pheochromocytoma in whom the
BV increased by more than 1.2 L, from a baseline value
of 2.83 L, after resection of the tumor [50]. Such
catecholamine-dependent changes in BV have been
confirmed in patients with pheochromocytoma after
alpha-blocker therapy. Norepinephrine is a potent α-
adrenergic agonist and less potent β-vasoconstrictor, and
it is used as a first-line treatment for the maintenance of
blood pressure in low pressure states and septic shock
[51]. The impact of norepinephrine on BV, however, is not
conclusive. Shibuya et al. used a method with 51Cr-labeled
erythrocytes to investigate the effect of norepinephrine
infusions during minor surgical procedures. In that study,
blood pressure increased by 30% and PV decreased by
12% [52]. Hifumi et al. examined the correlation between
norepinephrine and PV in hypertensive patients with high
catecholamine levels using 131I-labeled albumin and found
that norepinephrine was correlated with a low PV [53].
However, Rector et al. showed that high norepinephrine
levels are correlated with high BV levels in cirrhosis
patients with ascites [54]. ANP is secreted primarily by
ventricular myocytes in response to wall stress that has
been induced by volume load and increased pressure, and
ANP secretion is stimulated by the rapid infusion of a fluid
bolus. Some studies have failed to find a correlation
between BV and ANP [55-57], while others have shown
that the secretion of ANP decreases BV probably due to a
diuretic effect [58-60]. More interestingly, however, ANP
induces shedding of the glycocalyx, which facilitates trans-
location of fluid to the interstitial space [61]. Vane et al.
showed that isoproterenol, a non-specific β-adrenergic
agonist, and dopamine, a mixed β-adrenergic and dopa-
minergic agonist, increased PV while phenylephrine, a
pure α-adrenergic agonist, decreased PV [62]. Kinsky
et al. showed that esmolol, a β-adrenergic antagonist, de-
creased PV and increased extravascular volume [63,64].
Phenylephrine is commonly used for perioperative support
of blood pressure but reduces global cardiac output,
increases myocardial wall stress, and increases myocardial
oxygen requirements and should be reserved for hy-
pertrophic subaortic stenosis, tetralogy of Fallot, and
pregnancy where it results in less fetal acidosis compared
to ephedrine [65].
Dynamics of capillaries
As seen in Figure 2, there are two important barriers to
the distribution of fluids. First, there is the cell membrane,
which keeps the interior of the cell intact. Second, there is
the vascular endothelial barrier between the intravascular
and the extracellular spaces. Fluid movement across the
cell membrane is controlled mainly by osmotic forces and
Figure 2 Capillary with red blood cells and endothelial cells (EC). The inner lining of the glycocalyx and trapped plasma together form the
endothelial surface layer (ESL). A revised Starling formula would be as follows: Jv = Kf ([Pc – Pi] –Ώ[Πesl – Πb]) where Jv is the net filtration, Kf is the
filtration coefficient, Pc is the capillary hydrostatic pressure, Pi is the interstitial hydrostatic pressure, Ώ is the reflection coefficient, Πesl is the
oncotic pressure within the endothelial surface layer and Πb is the oncotic pressure beneath the endothelial surface layer. Within the ESL there is
practically no circulation [15]. EC: endothelial cell; ESL: endothelial surface layer.
Iijima et al. Perioperative Medicine 2013, 2:9 Page 4 of 12
http://www.perioperativemedicinejournal.com/content/2/1/9the forces governing fluid movement across the endothe-
lial (capillary) wall were first described by Starling in 1896
[66]. These forces describe an outward movement of fluid
due to the hydrostatic pressure on the arterial side of the
capillary while there is a slight inward movement on the
venous side. This is due to the colloid osmotic pressure
within the vessels produced by the protein content of the
plasma. Plasma hydrostatic and colloid osmotic pressures
are counteracted by weak interstitial hydrostatic and col-
loid osmotic pressures. The vascular wall is permeable to
water and small molecules but not to proteins or other
large molecules. If isotonic solutions are given, there are
no movements of fluid across the cell membrane and
fluids remain in the extracellular space. Under normal
conditions with an intact vascular barrier, there is a flow
of fluid and albumin across the barrier with fluid and al-
bumin returning via the lymph vessels.
Glycocalyx
The approach taken by Starling to describe the movement
of fluids across the endothelial wall is now known to be
too simplistic. The endothelium consists of a thin layer of
cells with an inner fragile layer, the endothelial glycocalyx
(EG), containing glycosaminoglycans (Figure 2). The
glycocalyx binds plasma proteins to form the endothelial
surface layer (ESL), which has a high internal oncotic
pressure. The low net flux passing through the EG has
low concentrations of proteins so the oncotic pressure
beneath this layer is low. The EG creates a barrier that
binds proteins and this prevents some erythrocytes from
moving close to it. Thus, there is a zone where almost no
circulation occurs and non-circulating protein-rich plasma
predominates. The intravascular volume can, therefore, be
considered to consist of circulating red cells and plasma
volume as well as a non-circulating plasma volume. The
function of the glycocalyx appears to be the maintenance
of an effective colloid osmotic pressure close to 70% of the
luminal osmotic pressure while keeping the colloid con-
centration outside the endothelium equal to that inside
the lumen of the microvessel [67]. Thus, transcapillaryfluid exchange seems to depend not on the difference
between the hydrostatic and oncotic pressures between
blood and tissue but, rather, between the blood and the
small space underneath the endothelial glycocalyx but still
within the lumen of the capillary. Destruction of the
glycocalyx, which can occur during trauma and septi-
cemia, will eventually cause a change in the global diffe-
rence between hydrostatic and oncotic pressures and this
will lead to a situation that is best described by the
concepts developed by Starling. If the interstitial colloid
osmotic pressure then equals that of the plasma, intersti-
tial edema will occur. Reduction or destruction of the EG
leads to platelet aggregation, leukocyte adhesion and
increased permeability, all of which are hallmarks of inter-
stitial edema. Factors that can cause destruction of the
EG are proteases, ischemia/reperfusion, tumor necrosis
factors, oxidized low density lipoproteins and atrial na-
triuretic peptide triggered by hypervolemia [15,67]. A goal
for the clinician should be to maintain normovolemia du-
ring surgery to protect the EG and minimize shifts to the
interstitium. Factors that have been shown experimentally
to protect the endothelium are hydrocortisone, antithrom-
bin and sevoflurane [68-70].
To determine fluid responsiveness during different
conditions, it is important to understand the impact of
different fluids. Over the past several decades, there has
been a debate as to whether clinicians should use crys-
talloids or colloids. This disagreement is based mostly
on tradition and local agreement on how fluid deficits
should be handled and seldom on an understanding
of the reason for the underlying pathophysiology. In de-
ciding the best course of treatment, fluids should be
considered as efficient drugs with their own unique impacts
on patients in regard to their pharmaceutical properties, in-
dications, contraindications and side effects.
Different fluids
Crystalloids
Crystalloids have a long history of use in clinical settings.
In the 1830 s saline solutions were occasionally given
Figure 3 Functional volumes in a two-fluid space model. R0 is
the infusion rate in mL/min, Vc is the central fluid space, vc is the
expanded central fluid space in liters, Vt is the peripheral fluid space,
vt is the expanded peripheral space in liters, Cl0 is the basal
elimination in mL/min, Cld is the interfluid space constant in mL/min
and Cl is the dilution dependent elimination in mL/min.
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is credited with having established the technique of giving
crystalloids in clinical practice. Ringer published ground-
breaking papers in 1882 verifying the importance of cer-
tain ions such as calcium and ammonium to make saline
solutions more physiological. Hartmann later added bu-
ffered ions to Ringer’s solution to offset its acidity.
Crystalloids are defined as solutions containing molecules
smaller than 30 kDa and thus lacking oncotic components.
When glucose is administered, the glucose is metabolized
in the liver leaving only water to be distributed to the ECV
and ICF, and only 7% of the infused fluid will remain in the
intravascular space (IVS). Isotonic crystalloids are distrib-
uted within the ECV and urine production and insensible
perspiration are the primary avenues by which water is lost
from the ECV. Insensible perspiration does not amount to
more than 0.5 mL/kg/h in awake adults [71]. Isotonic crys-
talloids, preferably in a balanced form to avoid acid–base
disorders [15], should theoretically be ideal for replacing
losses from the ECV. Because there is a 1:5 volume ratio
between the plasma space and ISF, it is estimated that 20%
to 25% of an infused crystalloid will reside in the plasma
space. The 1:5 distribution may only occur after a fluid
bolus has been entirely equilibrated throughout the ECV
during normal conditions, and provided that it still resides
in the body and has not been partially eliminated. This
means, however, that a crystalloid load may initially show a
substantial volume effect during an ongoing infusion [72].
The hydration status of the body also influences the distri-
bution of crystalloid solutions. This phenomenon is used in
the recently introduced volume loading test, which is used
to assess the hydration status of individual patients [73,74].
Tatara et al. showed that a 75 mL/kg crystalloid infusion
after hemorrhage momentarily restored BV during the infu-
sion. When the infusion was stopped, however, BV de-
creased rapidly to a volume lower than it had been
before the infusion [75]. This finding supports a concept
developed using homeostatic blood states theory that a
physiologic target BV will change according to changes
in red cell volume; for example, a decrease of red cells
after hemorrhage decreases the physiologic target BV by
the volume of lost red cells [73].
Volume kinetics is used to study the effect of an infused
bolus over time, and is similar to pharmacokinetic
methods for studying drug effects. This method uses an
endogenous tracer, hemoglobin, to calculate fractional
changes in plasma dilution over time [76]. Repeated sam-
pling of hemoglobin will produce a dilution curve. When
such a curve has been established for an individual pa-
tient, the values can be fitted to a non-linear equation that
will give estimates of the rate constants for distribution
and clearance in a similar manner to pharmacokinetics.
The method has been criticized, however, for being based
on calculations of estimated initial values of hemoglobinand for assessing changes only in the circulating part of
the BV [15]. Presumably, the method does not account for
the non-circulating part of the BV. However, volume kin-
etics is a pharmacokinetic tool measuring functional, not
anatomical, volumes and it is a useful tool to describe fluid
movement between spaces. An infused bolus of a crystal-
loid will allocate initially in central well-perfused spaces of
the body (Vc, approximately 3 L to 4 L). This space may or
may not correspond to the anatomical plasma space.
Subsequently, the fluid load will be transferred to a more
peripheral volume (Vt, 6 L to 8 L), which will be smaller
than the anatomical interstitial space (Figure 3). Vc be-
comes slightly larger if based on arterial rather than on
venous hemoglobin values [15]. The volume of Vt is 6 L to
8 L in adult males weighing 70 kg to 80 kg. In contrast to
earlier estimations using isotopes of sodium and bromide,
volume kinetics measures changes only in spaces that are
able to expand upon infusion of the fluid. There are
spaces, such as bone tissue, that cannot be expanded by
an infused fluid. Studying volume kinetics, it is also easy
to see that under ideal conditions in awake, healthy volun-
teers, an infused crystalloid is readily eliminated and thus
it is distributed based on a one-volume model. This is in
contrast to situations during trauma and hemorrhage
where the fluid has a tendency to stay in the body and a
two-volume model with little or no elimination is more
appropriate.
The volume kinetics models, however, are hampered by
two limitations. First, they require frequent and precise
hemoglobin sampling, which is not feasible clinically.
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generate substantial dilution curves. For the moment,
volume kinetics is a research tool for bettering our under-
standing of fluid movement. In the future, accurate non-
invasive measurement of hemoglobin levels may permit the
clinical use of volume kinetics methods. An example of the
kinetic profile of an infused crystalloid is given in Figure 4.
Colloids
There are a wide variety of colloids including starches,
dextrans, gelatines and albumin. Artificial colloids are
large macromolecules that consist of a variety of poly-
saccharides or polypeptides and are derived from either
plant or animal sources. The artificial colloids are mainly
diluted in either 0.9% saline or a balanced solution such
as acetated Ringer’s solution. These are in contrast to
albumin, which is a more heterogeneous colloid derived
from plasma. The main reason for using colloids is to
replace intravascular deficits due to events such as
hemorrhage or fluid shifting [15]. Colloid infusions
persist in the IVS for longer periods than crystalloid
infusions because it is more difficult for large molecules
to transverse an intact vascular barrier. Supposedly, the
colloids can contribute to hemodynamic stability with
less fluid in a shorter time. This is probably true in
healthy people. In sick patients, however, the endothelial
glycocalyx is often damaged leading to a leaking capillary
wall [15,77]. In studies of normovolemic hemodilution,
Rehm and co-workers showed that volume loading withFigure 4 Dilution curves (%, thin lines) for individuals. A non-
linear equation is, after iteration, fitted to the data generating a
mean dilution curve (thick line) from which parameter estimates for
distribution (Vc, Vt) and clearance (Cl) can be calculated [76]. The
initial dilution effect of the infused bolus is approximately 25% (0.25
on the y-axis) but the effect is transient. The fluid is almost
completely eliminated from the central space after 2 hours. The y-
axis is the percentage dilution and the x-axis is time in minutes. In
these individuals, infusion times were 10 minutes and the
experiment lasted for 120 minutes.colloids in normovolemia resulted in reduced volume
persistence (68%) than if blood had already been re-
moved (90%) [78]. Furthermore, it has been shown in
clinical studies that during leakiness the volume effects
of colloids are similar to that of crystalloids [79]. The
ratio could actually vary from 1: 1,2-1,4 for crystalloids
to colloids during these conditions [80]. The earliest evi-
dence of renal toxicity from hydroxyethylstarch (HES)
solutions came from case reports of osmotic nephrosis
[81]. Several clinical studies addressing this issue have
been inconclusive in critically ill patients [82-84]. Re-
cently, two large randomized clinical studies addressed
this issue in patients with sepsis and septic shock
[80,85]. The Scandinavian Starch for Severe Sepsis/Sep-
tic Shock Trial (6S) was an investigator-initiated, multi-
center, blinded, stratified, parallel-group clinical study
with randomization. Subjects received a study fluid in a
1:1 ratio for fluid resuscitation with either HES 130/0.42
in a balanced solution or Ringer’s acetate. The study
enrolled 800 patients with sepsis or septic shock in 26
centers in Scandinavia. The primary outcome was death
or a need for renal replacement therapy (RRT) at 90 days
after randomization. The study showed an increased
mortality and also a clear renal toxicity in the HES
group. The amount of trial fluid was approximately
3,000 mL in each group. However, the intervention came
after the patients had been initially resuscitated, and you
could argue that the patients received an unnecessary
amount of HES [80]. The Crystalloid versus Hydroxyethyl
Starch Trial (CHEST) enrolled 7,000 patients (including
1,937 with sepsis) and randomly assigned them to receive
either HES 130/0.4 in 0.9% saline or 0.9% saline alone for
all fluid resuscitation until discharge, death or 90 days.
The primary outcome was death within 90 days and sec-
ondary outcomes included RRT or acute kidney injury
(AKI). The inclusion criteria were quite similar to 6S but
in CHEST the HES group received approximately 30% less
fluid, had a faster increase in central venous pressure
(CVP) and a lower incidence of cardiac failure. There was
no significant difference in mortality at 90 days; however,
in CHEST, HES was linked with a greater use of RRT. Of
note, however, is that CHEST found a lower incidence of
AKI with HES than with saline. When it comes to AKI by
RIFLE criteria, CHEST favors saline as regards to creatin-
ine while it favors HES in connection with increased
urinary output [85]. However, low molecular weight col-
loids are widely used in goal-directed fluid protocols to
reach a predetermined response for elective patients in
surgical settings. Giving small aliquots of colloids up to a
predetermined target volume allows fluids to be adminis-
tered in a manner that more closely mimics natural
physiological processes, and takes into consideration indi-
vidual differences between patients [86-88]. This has im-
proved the outcome for patients although this comparison
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Whether starch solutions cause long-term renal toxicity
for these patients is a question to be answered. There is
currently no clinical or scientific indication that they do
but there have been no long-term follow-ups from this
perspective [89,90].
Can blood volume be measured?
Estimation of BV is difficult in the clinical setting and
the clinician is often faced with unspecific clinical signs
of hypovolemia and dehydration. Evaluation of skin
turgor, blood pressure, heart rate and urinary output are
not reliable and are unsuited for guiding fluid therapy
protocols. Invasive measurements such as pulmonary
artery pressure, central venous pressure and blood pres-
sure are all unreliable for detecting a fluid deficit [91].
Standard pressure preload measurements such as central
venous pressure and pulmonary capillary wedge pressure
may not reflect the true preload pressure [92]. Over the
past several years, thermodilution and echocardiographic
preload determination parameters have been shown to
be superior to measurements of the pulmonary capillary
wedge pressure [93,94]. In particular, the global end
diastolic volume measured by transpulmonary thermo-
dilution, the right ventricular end diastolic volume
assessed by a continuous thermodilution catheter, and
the left ventricular end diastolic volume assessed by
echocardiography are superior methods for determining
preload [92]. Many clinicians tend to look at urinary
output to guide fluid therapy but this is a highly non-
specific measurement. The passive leg-raising test is an
easy, and probably reliable, method to test for hypo-
volemia [95]. A semi-automated blood volume analyzer,
the BVA-100 (Daxor Corporation, NY, USA), uses a
radioisotope to measure BV at the bedside. This system
is used in conjunction with a single-use diagnostic kit,
which uses a flow chamber and an albumin 131I injectate
[21]. A determination of BV, PV and red cell volume with
this device takes about 30 minutes and has an accuracy of
±2.5%. Another interesting method is transcutaneous
pulse dye densitometry, which employs an optical probe
similar to that used in pulse oximetry to measure infused
intra-arterial ICG concentrations [30].
Zero-balanced protocols
When it became clear that aggressive fluid loading with
crystalloids was harmful for perioperative fluid manage-
ment [96], a more restrictive approach became apparent.
In thoracic surgery, fluid restriction became standard
practice, but in the general surgical population this was
more dependent on the discretion of the clinician. In
2003, Brandstrup and co-workers published a randomized
multicenter study comparing liberal and restrictive fluid
management strategies in colorectal surgery [1]. Thenumber of postoperative patients with complications was
significantly reduced in those receiving more restrictive
fluid therapies. This study looked at anastomotic leakage,
wound infection, and cardiovascular and pulmonary com-
plications, all of which were reduced when perioperative
fluid was limited. Postoperative weight gain was deter-
mined to be a negative factor from these limited treatment
protocols. This study has been widely cited and counts as
a major landmark study in its field, but it has been pointed
out that the restrictive group received more colloids com-
pared to the saline standard-of-care group. Several studies
have since addressed this topic and it can be concluded
that fluid amounts in groups considered restrictive and
liberal vary considerably. What is restrictive in one study
can very well be liberal in another and the types of surgery
also vary considerably in these studies. Some studies have
been performed on day surgical cases where the endpoints
(well-being, less nausea, vomiting and dizziness) are diffe-
rent compared to more high-risk surgical patients where
length of hospital stay and mortality are more relevant as
endpoints. Healthy subjects undergoing short procedures
seem to benefit from a moderate infusion of a crystalloid
to prevent postoperative nausea [97] while patients under-
going colorectal surgery have benefited from zero-balanced
protocols with a restrictive goal-directed protocol pattern,
even though the total amount of fluid could exceed that
administered during day surgery protocols due to the
length of surgery.
Individualized goal-directed therapy
Individualized fluid therapy is likely the best course of
action because patients differ in underlying pathology,
size and responsiveness to different physiological pertur-
bations. Therefore, it would be beneficial to be able to
determine the baseline hydration status for each individ-
ual. This task is, indeed, a challenge for the clinician and
significant amounts of research are directed towards
methods for finding the baseline hydration status of an
individual on the day of surgery. Intermittent estima-
tions of BV and the fluid status in different compart-
ments using an experimental tracer or dilution methods
are not clinically feasible. Instead, an ideal therapy would
measure responsiveness, which is the deviation of target
parameters induced by a fluid bolus. However, fluid re-
sponsiveness requires a dynamic assessment. The Frank–
Starling curve describes the relationship between diastolic
myocardial tension (preload) and systolic cardiac function
(Figures 5 and 6).
An increase in preload should cause an increase in cardiac
output. From the curve, it is possible to analyze which pa-
tients are responders and which are non-responders to fluid
therapy in the context of cardiovascular performance [17].
Functional hemodynamic parameters such as stroke volume
variation (SVV) and pulse pressure variation could possibly
Figure 5 The Frank–Starling curve showing the relationship
between diastolic myocardial tension (preload) and systolic
cardiac function (stroke volume). An increase in preload results in
a corresponding increase in stroke volume. Using the curve, it is
possible to analyze who is a responder and who is a non-responder
to fluid therapy. P: preload; SV: stroke volume.
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ters are dependent on the interaction between the heart and
the lungs (pulse contour analysis). In a spontaneously
breathing patient, inspiration will reduce the intrathoracic
pressure, which will augment venous return and the preload
thereby increasing stroke volume. In a mechanically venti-
lated patient, the opposite conditions will persist. This can
be observed clinically by studying the arterial waveform
during mechanical ventilation and seeing how the curve
moves. The movement of the curve can actually show theFigure 6 The correlation between stroke volume variation
(SVV) and the Frank–Starling curve. Round circles indicate
changes in SVV as more fluid is given. When SVV is below 10% to
12%, the patient is said to be a non-responder. SV: stroke volume;
SVV: stroke volume variation.degree of hypovolemia. Variations imposed on the Frank–
Starling curve can result in major alterations if imposed in
the lower part of the curve, but only minor alterations will
occur if imposed on the flatter part.
Different monitoring systems
An example of an invasive device is the PiCCO (Pulsion
Medical Systems, Munich, Germany), which enables con-
tinuous hemodynamic monitoring using a femoral or
axillary arterial catheter and a central venous catheter.
Employing patented algorithms based on the assumption
that the area under the systolic part of the aortic pressure
waveform corresponds to the stroke volume curve, PiCCO
combines real-time continuous monitoring through pulse
contour analysis with intermittent thermodilution meas-
urement via the transpulmonary method. This device is
able to give measurements of the transpulmonary cardiac
output, intrathoracic blood volume, extravascular lung
water and cardiac function. The latter parameters require
a central venous line for injection of a cold bolus. The
system, however, requires recalibrations, especially when
rapid changes occur [99].
The LiDCO technique (LiDCO Ltd, London, UK) is
another pulse contour method (or pulse power method),
based on a purported linear relationship between net
power and net flow in the vascular system provided that
no major change in vascular compliance or resistance oc-
curs. The LiDCO plus technique requires lithium dilution
and gives a reliable assessment of cardiac output and
stroke volume provided the restrictions mentioned above
are met. The LiDCO rapid version does not require cali-
bration and is used solely for monitoring cardiac output
and stroke volume deviations from baseline [100].
The FloTrac and Vigileo (Edwards Inc., Irvine, CA)
systems requires a sensor attached to an arterial line.
The system continually displays cardiac output (CO) and
SVV, which can be correlated to the Frank–Starling
curve as seen in Figure 6. For the Vigileo system, the
standard deviation of pulse pressure is correlated with a
normal stroke volume based on an underlying database.
Aortic impedance is also derived from historic data, but
actual vascular compliance and resistance are deter-
mined using arterial waveform analysis. The device does
not require calibration and is fairly easy to use but is
hampered by the fact that it is less reliable when vaso-
pressors are used [101]. Even the latest software, version
3, is not accurate when a common vasopressor such as
phenylephrine is used. Furthermore, an optimal arterial
signal is needed for valid cardiac output measurement.
SVV measurements are also limited by the requirement of
mechanical ventilation with a tidal volume of at least 8 ml/
kg [91]. A new device package, the EV 1000 (Edwards Inc.,
Irvine, CA), combines the FloTrac system with the PreSep/
PediaSet oximetry catheters to provide central venous
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hemodynamic and volumetric data. The use of this device
has recently been approved by the FDA in the US. All of
these devices require optimal arterial signals and are unre-
liable when the patient has arrhythmias or is undergoing
intra-aortic balloon pump treatment.
Recently, non-invasive methods have been presented
such as plethysmographic systolic pressure variation and
the plethysmographic variability index (Masimo Inc., Irvine,
CA). These methods also require the patient to be mechan-
ically ventilated. However, this could enhance perioperative
monitoring [102].
Esophageal Doppler-guided therapy (ED) uses Doppler
ultrasound technology to analyze the blood flow in the
descending aorta. A single-use probe is inserted into the
esophagus and positioned to measure the blood flow for
each heartbeat. The waveform is then compared to bio-
metric data and gives the stroke volume. Because the
catheter is inserted in the lower esophagus, approxi-
mately 70% of the circulating blood flow is accounted
for in the calculations. Various algorithms are used to
measure fluid responsiveness. Most algorithms use small
aliquots of colloids (2 to 3 mL/kg). The primary goal of
the technique is to optimize the stroke volume according
to the Frank–Starling curve. The stepwise fluid infusion is
continued until the patient is considered a non-responder
to fluid. Usually this happens when stroke volume or
cardiac output deviation becomes <10%. This has been
validated against standard-of-care protocols; reduced mor-
bidity and reduced length of hospital stay have been
shown [87,103-106]. The ED technique has been used
in high-risk and colorectal surgery, but recent studies
showed no differences between ED and a fixed protocol in
more healthy patients or patients undergoing laparoscopic
procedures [107,108].
Conclusions and clinical guidelines
To conclude, the evidence-based recommendations are
that intraoperative fluid therapy should aim to administer
an adequate and timely volume-preserving flow to pertin-
ent organs. Healthy subjects undergoing short procedures
seem to benefit from a moderate infusion of a crystalloid
[97]. This will offset minor postoperative complications
such as nausea and vomiting.
High-risk patients, on the other hand, benefit from a
carefully monitored fluid regimen based on individualized
goal-directed therapy. This can be done in several diffe-
rent ways. The term restrictive is purposefully avoided
because this is dependent on where on the Frank–Starling
curve one starts the fluid regimen. It is important, there-
fore, to determine the patient’s responsiveness to fluid
therapy. This means that fluid therapy should be moderate
and individually tailored to each patient’s needs. Goal-
directed therapy using the esophageal doppler techniquehas been widely popular, and even nationally recom-
mended in the UK, but compared to modest regimens it
has been difficult to show improvements in outcome with
this technique [106]. A combination of SVV-guided fluid
therapy and oximetric guidance (PreSep/ScvO2) is prob-
ably more useful for high-risk surgery provided that the
arterial waveform is readable. This should be accompanied
by a moderate crystalloid infusion (1 to 2 mL/kg/h).
The choice of whether crystalloids or colloids should
be used is probably less important. Crystalloids should
mainly be used for losses from the ECV and colloids for
losses from the IVS. However, low molecular starches
should be avoided when patients have damaged endothe-
lium as in sepsis [85]. There is currently no full consen-
sus but albumin may be a better choice for these
patients [107].Abbreviations
6S: Scandinavian Starch for Severe Sepsis/Septic Shock Trial;
ADH: Antidiuretic hormone; AKI: Acute kidney injury; ANP: Atrial natriuretic
peptide; BV: Blood volume; CHEST: Crystalloid versus Hydroxyethyl Starch
Trial; Cl: Dilution-dependent clearance (elimination) in mL/min; Cl0: Basal
clearance (elimination) in mL/min; Cld: Interfluid space constant in mL/min;
CO: Cardiac output; COP: Colloid osmotic pressure; CVP: Central venous
pressure; EC: Endothelial cell; ECV: Extracellular fluid volume; ED: Esophageal
Doppler-guided therapy; EG: Endothelial glycocalyx; ESL: Endothelial surface
layer; HES: Hydroxyethyl starch; ICF: Intracellular fluid space; ICG: Indocyanine
green; ISF: Interstitial fluid space; IVS: Intravascular space; P: Preload;
PV: Plasma volume; R0: Infusion rate in mL/min; RAAS: Renin angiotensin
aldosterone system; RIFLE: Risk, injury, failure, loss, end stage kidney disease;
RISA: Radio-iodinated serum albumin; RRT: Renal replacement therapy;
ScvO2: Central venous oxygen saturation; SV: Stroke volume; SVV: Stroke
volume variation; TBW: Total body water; Vc: Central volume in L;
vc: Expanded central volume in L; Vt: Peripheral volume in L; vt: Expanded
peripheral volume in L.Competing interests
Takehiko Iijima receives lecture fees from Fresenius KABI Co. Ltd., Japan, and
Otsuka Pharmaceutical Co. Ltd., Japan.
Audrius Andrijauskas received a consultant’s fee from Masimo Corp. of Irvine,
CA, USA. Audrius Andrijauskas is an inventor on US Patent No. 7,788,045 B2,
PCT International patent application PCT/US2011/057,362, and US provisional
patent application No. 61/692,904.
Christer Svensen receives lecture fees from Fresenius KABI, Uppsala, Sweden,
and has intermittently been a member of the Masimo Inc. Advisory Board.
There are no other competing interests.Authors’ contributions
TI came up with the original idea for this manuscript. He contributed to the
design and helped to draft the manuscript. BB, PR and AA contributed to
the design and helped to draft the manuscript. CS contributed to the
design, helped to draft the manuscript and was also responsible for the final
revision of the text. All authors read and approved the final manuscript.
Author details
1Department of Perioperative Medicine, Division of Anesthesiology, School of
Dentistry, Showa University. 2Department of Surgical Gastroenterology,
Hvidovre University Hospital, Copenhagen, Denmark. 3Karolinska Institutet,
Department of Clinical Science and Education, Section of Anesthesiology
and Intensive Care, Södersjukhuset, Stockholm, Sweden. 4Clinic of
Anesthesiology and Intensive Care, Vilnius University, Vilnius, Lithuania.
Received: 20 September 2012 Accepted: 11 March 2013
Published: 7 May 2013
Iijima et al. Perioperative Medicine 2013, 2:9 Page 10 of 12
http://www.perioperativemedicinejournal.com/content/2/1/9References
1. Brandstrup B, Tønnesen H, Beier-Holgersen R, Hjortsø E, Ørding H, Lindorff-
Larsen K, et al: Effects of intravenous fluid restriction on postoperative
complications: comparison of two perioperative fluid regimens. Ann Surg
2003, 238:641–648.
2. Holte K, Sharrock NE, Kehlet H: Pathophysiology and clinical implications
of perioperative fluid excess. Br J Anaesth 2002, 89:622–632.
3. Nisanevich V, Felsenstein I, Almogy G, Weissman C, Einav S, Matot I: Effect
of intraoperative fluid management on outcome after intraabdominal
surgery. Anesthesiology 2005, 103:25–32.
4. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D,
DeBoisblanc B, et al: Comparison of two fluid-management strategies in
acute lung injury. N Engl J Med 2006, 354:2564–2575.
5. Jacob M, Chappell D, Rehm M: Clinical update: perioperative fluid
management. Lancet 2007, 369:1984–1986.
6. Brandstrup B: Fluid therapy for the surgical patient. Best Pract Res Clin
Anaesthesiol 2006, 20:265–283.
7. Crenshaw CA, Canizaro PC, Shires GT, Allsman A: Changes in extracellular
fluid during acute hemorrhagic shock in man. Surg Forum 1962, 13:6–7.
8. Shires GT, Coln D, Carrico J, Lightfoot S: Fluid therapy in hemorrhagic
shock. Arch Surg 1964, 88:688–693.
9. Shires GT, Williams J, Brown F: Acute changes in extracellular fluid
associated with major surgical procedures. Ann Surg 1961, 154:803–810.
10. Brandstrup B, Svensen C, Engquist A: Hemorrhage and surgery cause a
contraction of the extracellular space needing replacement – evidence
and implications? Surgery 2006, 139:419–432.
11. Jackson R, Reid JA, Thorburn J: Volume preloading is not essential to
prevent spinal-induced hypotension at Caesarean section. Br J Anaesth
1995, 75:262–265.
12. Norberg A, Brauer KI, Prough DS, Gabrielsson J, Hahn RG, Uchida T, et al:
Volume turnover kinetics of fluid shifts after hemorrhage, fluid infusion,
and the combination of hemorrhage and fluid infusion in sheep.
Anesthesiology 2005, 102:985–994.
13. Jacob M, Chappell D, Conzen P, Finsterer U, Rehm M: Blood volume is
normal after pre-operative overnight fasting. Acta Anaesthesiol Scand
2008, 52:522–529.
14. Bundgaard-Nielsen M, Holte K, Secher NH, Kehlet H: Monitoring of peri-
operative fluid administration by individualized goal-directed therapy.
Acta Anaesthesiol Scand 2007, 51:331–340.
15. Chappell D, Jacob M, Hofmann-Kiefer K, Conzen P, Rehm M: A rational
approach to perioperative fluid management. Anesthesiology 2008,
109:723–740.
16. Holte K, Foss NB, Andersen J, Valentiner L, Lund C, Bie P, et al: Liberal or
restrictive fluid administration in fast-track colonic surgery: a
randomized, double-blind study. Br J Anaesth 2007, 99:500–508.
17. Hofer CK, Cannesson M: Monitoring fluid responsiveness. Acta Anaesthesiol
Taiwan 2011, 49:59–65.
18. Sheng HP, Huggins RA: A review of body composition studies with
emphasis on total body water and fat. Am J Clin Nutr 1979, 32:630–647.
19. Dworkin HJ, Premo M, Dees S: Comparison of red cell and whole blood
volume as performed using both chromium-51-tagged red cells and
iodine-125-tagged albumin and using I-131-tagged albumin and
extrapolated red cell volume. Am J Med Sci 2007, 334:37–40.
20. Ertl AC, Diedrich A, Raj SR: Techniques used for the determination of
blood volume. Am J Med Sci 2007, 334:32–36.
21. Fairbanks VF, Klee GG, Wiseman GA, Hoyer JD, Tefferi A, Petitt RM, et al:
Measurement of blood volume and red cell mass: re-examination of 51Cr
and 125I methods. Blood Cells Mol Dis 1996, 22:169–186.
22. Bradley EC, Barr JW: Determination of blood volume using indocyanine
green (cardio-green) dye. Life Sci 1968, 7:1001–1007.
23. Nadler SB, Hidalgo JU, Bloch T: Prediction of blood volume in normal
human adults. Surgery 1962, 51:224–232.
24. Morgan GE, Mikhail MS, Murray MJ: Clinical Anesthesiology. New York: Lange
Medical Books/McGraw Hill; 2005.
25. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, et al:
Interpretation of measured red cell mass and plasma volume in adults:
Expert Panel on Radionuclides of the International Council for
Standardization in Haematology. Br J Haematol 1995, 89:748–756.
26. Bremer F, Schiele A, Sagkob J, Palmaers T, Tschaikowsky K: Perioperative
monitoring of circulating and central blood volume in cardiac surgery
by pulse dye densitometry. Intensive Care Med 2004, 30:2053–2059.27. Jones JG, Holland BM, Hudson IR, Wardrop CA: Total circulating red cells
versus haematocrit as the primary descriptor of oxygen transport by the
blood. Br J Haematol 1990, 76:288–294.
28. Guyton AC, Hall JE: Textbook of Medical Physiology. 9th edition. Philadelphia:
W.B. Saunders; 1996:123–148.
29. Convertino VA: Blood volume response to physical activity and inactivity.
Am J Med Sci 2007, 334:72–79.
30. Iijima T, Iwao Y, Sankawa H: Circulating blood volume measured by pulse
dye-densitometry. Comparison with 131I-HSA analysis. Anesthesiology
1998, 89:1329–1335.
31. Hahn R, Brauer LP, Rodhe P, Svensen C, Prough DS: Isoflurane inhibits
transcapillary compensatory volume expansion. Anesth Analg 2006,
103:350–358.
32. Järhult J, Holmberg J, Lundvall J, Mellander S: Hyperglycemic and
hyperosmolar responses to graded hemorrhage. Acta Physiol Scan 1976,
97:470–475.
33. Zollinger RM Jr: Plasma volume and protein restoration after
hemorrhage: role of the left thoracic duct versus transcapillary refilling.
J Surg Res 1972, 12:151–160.
34. Drucker WR, Chadwick CDJ, Gann DS: Transcapillary refill in hemorrhage
and shock. Arch Surg 1981, 116:1344–1353.
35. Rieger A: Changes in blood volume and plasma proteins after trauma
and immediate substitution with different substitutes. Bibl Haematol
1969, 33:159–170.
36. Breckenridge IM, Digerness SB, Kirklin JW: Validity of concept of increased
extracellular fluid after open heart surgery. Surg Forum 1969, 20:169–171.
37. Breckenridge IM, Digerness SB, Kirklin JW: Increased extracellular fluid after
open intracardiac operation. Surg Gyn Obst 1970, 131:53–56.
38. Cohn LH, Angell WW: Relative extracellular fluid deficits in patients
undergoing coronary artery bypass. Surg Forum 1971, 22:151–152.
39. Cleland J, Pluth JR, Tauxe WN, Kirklin JW: Blood volume and body fluid
compartment changes soon after closed and open intracardiac surgery.
J Thorac Cardiovasc Surg 1966, 52:698–705.
40. Ariel IM: Metabolic alterations induced by intra-abdominal operations.
Ann Surg 1953, 138:186–202.
41. Roth E, Lax LC, Maloney JV: Ringer’s lactate solution and extracellular fluid
volume in the surgical patient: a critical analysis. Ann Surg 1969, 169:149–164.
42. Reid DJ: Intracellular and extracellular fluid volume during surgery. Br J
Surg 1968, 55:594–596.
43. Gutelius JR, Shizgal HM, Lopez G: The effect of trauma on extracellular
water volume. Arch Surg 1968, 97:206–214.
44. Ladegaard-Pedersen HJ, Engell HC: A comparison between the changes in
the distribution volumes of inulin and [51Cr]EDTA after major surgery.
Scand J Clin Lab Invest 1975, 35:109–113.
45. Nielsen OM, Engell HC: Extracellular fluid volume and distribution in
relation to changes in plasma colloid osmotic pressure after major
surgery. A randomized study. Acta Chir Scand 1985, 151:221–225.
46. Fukuda Y, Fujita T, Shibuya J, Albert SN: The distribution between the
intravascular and interstitial compartments of commonly utilized
replacement fluids. Anesth Analg 1969, 48:831–838.
47. Rehm M, Orth V, Kreimeier U, Thiel M, Haller M, Brechtelsbauer H, et al:
Changes in intravascular volume during acute normovolemic
hemodilution and intraoperative retransfusion in patients with radical
hysterectomy. Anesthesiology 2000, 92:657–664.
48. Rehm M, Haller M, Brechtelsbauer H, Akbulut C, Finsterer U: Extra protein
loss not caused by surgical bleeding in patients with ovarian cancer.
Acta Anaesthesiol Scand 1998, 42:39–46.
49. Chapman CR, Tuckett RP, Song CW: Pain and stress in a systems
perspective: reciprocal neural, endocrine, and immune interactions.
J Pain 2008, 9:122–145.
50. Iijima T, Takagi T, Iwao Y: An increased circulating blood volume does not
prevent hypotension after pheochromocytoma resection. Can J Anaesth
2004, 51:212–215.
51. Vincent JL, Gottin L: Type of fluid in severe sepsis and septic shock.
Minerva Anestesiol 2011, 77:1190–1196.
52. Shibuya J, Bageant W, Gonzalez P, Small F, Albert S: Comparison of effect
of norepinephrine and angiotensin on blood volume and viscosity.
Anesthesiology 1964, 25:109–110.
53. Hifumi S, Morise T, Honjo A, Fujimura A, Uchida K, Saito Z, et al: Total blood
volume in essential and secondary hypertension. Nihon Naibunpi Gakkai
Zasshi 1982, 58:790–795.
Iijima et al. Perioperative Medicine 2013, 2:9 Page 11 of 12
http://www.perioperativemedicinejournal.com/content/2/1/954. Rector WG Jr, Hossack KF: Pathogenesis of sodium retention complicating
cirrhosis: is there room for diminished ‘effective’ arterial blood volume?
Gastroenterology 1988, 95:1658–1663.
55. Katzarski KS, Randmaa I, Bergstrom J: Influence of hemodialysis on
intravascular volume and vasoactive hormones. Clin Nephrol 1999,
52:304–311.
56. Morishita Y, Ando Y, Ishii E, Arisaka M, Kusano E: Comparison of markers of
circulating blood volume in hemodialysis patients. Clin Exp Nephrol 2005,
9:233–237.
57. Krieger JE, Cowley AW Jr: Prevention of salt angiotensin II hypertension
by servo control of body water. Am J Physiol 1990, 258:H994–H1003.
58. Trippodo NC, Cole FE, Frohlich ED, MacPhee AA: Atrial natriuretic peptide
decreases circulatory capacitance in areflexic rats. Circ Res 1986, 59:291–296.
59. Jespersen B, Eiskjaer H, Pedersen EB: Effect of atrial natriuretic peptide on
blood pressure, guanosine 3':5'-cyclic monophosphate release and blood
volume in uraemic patients. Clin Sci (Lond) 1990, 78:67–73.
60. Wijeyaratne CN, Moult PJ: The effect of alpha human atrial natriuretic
peptide on plasma volume and vascular permeability in normotensive
subjects. J Clin Endocrinol Metab 1993, 76:343–346.
61. Bruegger D, Jacob M, Rehm M, Loetsch M, Welsch U, Conzen P, et al: Atrial
natriuretic peptide induces shedding of endothelial glycocalyx in
coronary vascular bed of guinea pig hearts. Am J Physiol Heart Circ Physiol
2005, 289:H1993–H1999.
62. Vane LA, Prough DS, Kinsky MA, Williams CA, Grady JJ, Kramer GC: Effects of
different catecholamines on the dynamics of volume expansion of
crystalloid infusion. Anesthesiology 2004, 101:1136–1144.
63. Kinsky MP, Vaid SU, Vane LA, Prough DS, Kramer GC: Effect of esmolol on
fluid therapy in normovolaemia and hypovolaemia. Shock 2008, 30:55–63.
64. Stephens CT, Uwaydah N, Kramer GC, Prough DS, Salter M, Kinsky MP:
Vascular and extravascular volume expansion of dobutamine and
norepinephrine in normovolemic sheep. Shock 2011, 36:303–311.
65. Thiele RH, Nemergut EC, Lynch C III: The clinical implications of isolated
alpha(1) adrenergic stimulation. Anesth Analg 2011, 113:297–304.
66. Starling EH: On the absorption of fluids from the connective tissue
spaces. J Physiol 1896, 19:312–326.
67. Chappell D, Jacob M, Paul O, Mehringer L, Newman W, Becker BF: Impaired
glycocalyx barrier properties and increased capillary tube haematocrit.
J Physiol 2008, 586:4585–4586.
68. Bruegger D, Rehm M, Abicht J, Paul JO, Stoeckelhuber M, Pfirrmann M, et al:
Shedding of the endothelial glycocalyx during cardiac surgery: on-pump
versus off-pump coronary artery bypass graft surgery. J Thorac Cardiovasc
Surg 2009, 138:1445–1447.
69. Becker BF, Chappell D, Bruegger D, Annecke T, Jacob M: Therapeutic
strategies targeting the endothelial glycocalyx: acute deficits, but great
potential. Cardiovasc Res 2010, 87:300–310.
70. Annecke T, Chappell D, Chen C, Jacob M, Welsch U, Sommerhoff CP, et al:
Sevoflurane preserves the endothelial glycocalyx against ischaemia-
reperfusion injury. Br J Anaesth 2010, 104:414–421.
71. Lamke LO, Nilsson GE, Reithner HL: Water loss by evaporation from the
abdominal cavity during surgery. Acta Chir Scand 1977, 143:279–284.
72. Svensen C, Hahn RG: Volume kinetics of Ringer solution, dextran 70, and
hypertonic saline in male volunteers. Anesthesiology 1997, 87:204–212.
73. Andrijauskas A: Homeostatic blood states theory, Thesis. Vilnius University
Clinic of Anaesthesiology and Intensive Care; 2006. http://www.dissertation.
com/book.php?method=ISBN&book=1599426536.
74. Andrijauskas A, Svensen C, Ivaskevicius J, Porvaneckas N, Kvederas G,
Marmaite U: Goal directed fluid therapy revised: indirect monitoring of
interstitial fluid accumulation during mini fluid challenges with
crystalloids. Open Conf Proc J 2012, 3:42–51.
75. Tatara T, Tsunetoh T, Tashiro C: Crystalloid infusion rate during fluid
resuscitation from acute hemorrhage. Br J Anaesth 2007, 99:212–217.
76. Hahn RG: Volume kinetics for infusion fluids. Anesthesiology 2009, 113:470–481.
77. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, et al:
Effects of hydroxyethylstarch and gelatin on renal function in severe
sepsis: a multicentre randomised study. Lancet 2001, 357:911–916.
78. Rehm M, Haller M, Orth V, Kreimeier U, Jacob M, Dressel H, et al: Changes
in blood volume and haematocrit during acute preoperative volume
loading with 5% albumin or 6% hetastarch solutions in patients before
radical hysterectomy. Anesthesiology 2001, 95:849–856.
79. Reinhart K, Hartog CS: Hydroxyethyl starch in patients with trauma. Br J
Anaesth 2012, 108:321–322.80. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A,
et al: Hydroxyethyl starch 130/0.4 versus Ringer’s acetate in severe
sepsis. N Engl J Med 2012, 367:124–134.
81. Dickenmann M, Oettl T, Mihatsch MJ: Osmotic nephrosis: acute kidney
injury with accumulation of proximal tubular lysosomes due to
administration of exogenous solutes. Am J Kidney Dis 2008, 51:491–503.
82. Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, et al:
Assessment of hemodynamic efficacy and safety of 6%
hydroxyethylstarch 130/0.4 versus 0.9% NaCl fluid replacement in
patients with severe sepsis: The CRYSTMAS study. Crit Care 2012, 16:R94.
83. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et
al: Intensive insulin therapy and pentastarch resuscitation in severe
sepsis. N Engl J Med 2008, 358:125–139.
84. Brunkhorst FM, Schortgen F: Effects of hydroxyethyl starch in critically ill
patients. Br J Anaesth 2007, 98:842–843.
85. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al:
Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N
Engl J Med 2012, 367:1901–1911.
86. Gan TJ, Soppitt A, Maroof M, El-Moalem H, Robertson KM, Moretti EW, et al:
Goal-directed intraoperative fluid administration reduces length of
hospital stay after major surgery. Anesthesiology 2002, 97:820–826.
87. Wakeling H, McFall M, Jenkins C, et al: Intraoperative oesophageal Doppler
guided fluid management shortens postoperative hospital stay after
major bowel surgery. Br J Anaes 2005, 95:634–642.
88. Hamilton MA, Cecconi M, Rhodes A: A systematic review and meta-
analysis on the use of preemptive hemodynamic intervention to
improve postoperative outcomes in moderate and high-risk surgical
patients. Anesth Analg 2011, 112:1392–1402.
89. Van Der Linden P, James M, Mythen M, Weiskopf RB: Review article: safety
of modern starches used during surgery. Anesth Analg 2013, 116:35–48.
90. Martin C, Jacob M, Vicaut E, Guidet B, Van Aken H, Kurz A: Effect of waxy
maize-derived hydroxyethyl starch 130/0.4 on renal function in surgical
patients. Anesthesiology 2013, 118:387–394.
91. Manoach S, Weingart SD, Charchaflieh J: The evolution and current use of
invasive hemodynamic monitoring for predicting volume responsiveness
during resuscitation, perioperative, and critical care. J Clin Anesth 2012,
24:242–250.
92. Hofer CK, Furrer L, Matter-Ensner S, Maloigne M, Klaghofer R, Genoni M, et
al: Volumetric preload measurement by thermodilution: a comparison
with transoesophageal echocardiography. Br J Anaesth 2005, 94:748–755.
93. Marik PE, Baram M, Vahid B: Does central venous pressure predict fluid
responsiveness? A systematic review of the literature and the tale of
seven mares. Chest 2008, 134:172–178.
94. Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ, et al: A
randomized, controlled trial of the use of pulmonary-artery catheters in
high-risk surgical patients. N Eng J Med 2003, 348:5–13.
95. Monnet X, Rienzo M, Osman D, Anguel N, Richard C, Pinsky MR, et al:
Passive leg raising predicts fluid responsiveness in the critically ill. Crit
Care Med 2006, 34:1402–1407.
96. Moore FD, Shires GT: Moderation. Ann Surg 1967, 166:300–301.
97. Holte K, Klarskov B, Christensen D, Lund C, Nielsen K, Bie P, et al: Liberal vs
restrictive fluid administration to improve recovery after laparoscopic
cholecystectomy: a randomised, double-blind study. Ann Surg 2004, 240:892–899.
98. Michard F, Boussat S, Chemla D, Anguel N, Mercat A, Lecarpentier Y, et al:
Relation between respiratory changes in arterial pulse pressure and fluid
responsiveness in septic patients with acute circulatory failure. Am J
Respir Crit Care Med 2000, 162:134–138.
99. Hofer CK, Ganter MT, Zollinger A: What technique should I use to measure
cardiac output? Curr Opin Crit Care 2007, 13:308–317.
100. Mora B, Ince I, Birkenberg B, Skhirtladze K, Pernicka E, Ankersmit HJ, et al:
Validation of cardiac output measurement with the LiDCO pulse contour
system in patients with impaired left ventricular function after cardiac
surgery. Anaesthesia 2011, 66:675–681.
101. Meng L, Tran NP, Alexander BS, Laning K, Chen G, Kain ZN, et al: The
impact of phenylephrine, ephedrine, and increased preload on third-
generation Vigileo-FloTrac and esophageal Doppler cardiac output
measurements. Anesth Analg 2011, 113:751–757.
102. Cannesson M, Desebbe O, Rosamel P, Delannoy B, Robin J, Bastien O, et al:
Pleth variability index to monitor the respiratory variations in the pulse
oximeter plethysmographic waveform amplitude and predict fluid
responsiveness in the operating theatre. Br J Anaesth 2008, 101:200–206.
Iijima et al. Perioperative Medicine 2013, 2:9 Page 12 of 12
http://www.perioperativemedicinejournal.com/content/2/1/9103. Mythen MG, Webb AR: Intra-operative gut mucosal hypoperfusion is
associated with increased post-operative complications and cost.
Intensive Care Med 1994, 20:99–104.
104. Sinclair S, James SA, Singer M: Intraoperative intravascular volume
optimisation and length of hospital stay after repair of proximal femur
fracture: randomised controlled trial. BMJ 1997, 315:909–912.
105. Venn R, Steele A, Richardson PL, Poloniecki JD, Grounds M, Newman PJ:
Randomized controlled trial to investigate influence of the fluid
challenge on duration of hospital stay and perioperative morbidity in
patients with hip fractures. Br J Anaesth 2002, 88:65–71.
106. Abbas SM, Hill AG: Systematic review of the literature for the use of
oesophageal Doppler monitor for fluid replacement in major abdominal
surgery. Anaesthesia 2008, 63:44–51.
107. Brandstrup B, Svendsen PE, Rasmussen M, Belhage B, Rodt SA, Hansen B, et
al: Which goal for fluid therapy during colorectal surgery is followed by
the best outcome: near-maximal stroke volume or zero fluid balance? Br
J Anaesth 2012, 109:191–199.
108. Challand C, Struthers R, Sneyd JR, Erasmus PD, Mellor N, Hosie KB, et al:
Randomized controlled trial of intraoperative goal-directed fluid therapy
in aerobically fit and unfit patients having major colorectal surgery. Br J
Anaesth 2012, 108:53–62.
doi:10.1186/2047-0525-2-9
Cite this article as: Iijima et al.: The maintenance and monitoring of
perioperative blood volume. Perioperative Medicine 2013 2:9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
